The company’s revenue contracted by 2.2% to $4.4 billion during the quarter. This decline was largely driven by a cooling generic segment, where the market for a generic version of the blood-cancer drug Revlimid became increasingly crowded. To counter these headwinds, Teva is accelerating its transition toward proprietary medicine. Sales for its three core brand-name products surged 33%, reaching $1.1 billion and providing a vital buffer against the generic slowdown.
In section Market Quotes
Teva Shifts Strategy as Branded Drugs Offset Generic Slump
Teva Pharmaceutical Industries reported a decline in third-quarter net income to $233 million, down from $433 million a year ago, as intensified competition in the generic market squeezed margins. Despite the dip, the company raised its 2026 revenue guidance, signaling confidence in its pivot toward high-growth branded treatments.
Looking ahead, the company adjusted its 2026 outlook, projecting revenue between $16.7 billion and $17 billion. This upward revision follows the recent FDA approval of Weltruza, a new schizophrenia treatment. With adjusted earnings per share landing at 86 cents for the quarter, management is betting that these specialty drugs will anchor future profitability as the generic business faces ongoing pressure.
Comments (0)
No comments yet. Be the first!